Immunomodulatory imide drug

Foghorn Therapeutics Announces New Data Demonstrating BRD9 Degradation in Patient Tumor Biopsies and Discloses New Selective CBP Program

Retrieved on: 
Wednesday, October 26, 2022
Lung, Synovial sarcoma, Chromatin, Company, Clinical trial, Security (finance), CBP, LinkedIn, U.S. Securities and Exchange Commission, Safety, Nasdaq, Forward-looking statement, Immunomodulatory imide drug, Hanson, Foghorn, Gene expression, Patient, Breast, IV, Research, GLOBE, Twitter, Therapy, BRD9, Ligament, Selective, Sarcoma, Cancer, CREB, Vaccine, Pharmaceutical industry, EP300

CAMBRIDGE, Mass., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today will present new data across its protein degradation platform at Hanson Wade’s 5th Annual Targeted Protein Degradation Summit. Early clinical data from the ongoing Phase 1 study of FHD-609 in synovial sarcoma and preclinical data from a newly disclosed program targeting CREB binding protein (CBP) in EP300 mutated cancers reinforce Foghorn’s significant advancement across its protein degradation platform and pipeline.

Key Points: 
  • We demonstrate highly potent and specific degradation of BRD9 with FHD-609 and, more significantly, in vivo loss of BRD9 in patient solid tumors.
  • Additionally, we are excited to announce our new protein degrader program, Selective CBP, which has potential broad therapeutic applications in cancer.
  • Foghorn will also include preclinical data highlighting the development of an orally bioavailable BRD9 selective degrader, demonstrating capabilities for both oral and IV formulations.
  • During the conference, Foghorn will also disclose the addition of its selective CBP degrader targeting EP300 mutant cancers to its pipeline.

Kymera Therapeutics to Hold Investor Webcast on December 14 to Share Clinical Data from KT-474 Phase I Patient Cohort and Oncology Pipeline

Retrieved on: 
Thursday, October 13, 2022
LinkedIn, U.S. Securities and Exchange Commission, Therapy, Risk, HS, IND, Science, AML, MAD, MDM2, Degenerative disease, Annual report, NASDAQ, Neoplasm, Patient, Biotechnology, Twitter, Security (finance), STAT3, Immunomodulatory imide drug, Boston Business Journal, Sanofi, Nasdaq, Precision medicine, Private Securities Litigation Reform Act, Boston, Single, PBMC, Lymphatic system, DLBCL, Atopic dermatitis, Adult, Safety, SAD, Food, AD, Skin, Lymphoma, GLOBE, Plasma, Apoptosis, COVID-19, Cancer, Pharmaceutical industry, Medicine, Medical imaging, Part, IRAK4, Black Majesty

WATERTOWN, Mass., Oct. 13, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, will hold an investor webcast on December 14 to present clinical data from the KT-474 Phase 1 HS and AD patient cohort (Part C) and its oncology pipeline.

Key Points: 
  • Kymera recently completed dosing in Part C of the Phase 1 clinical trial evaluating its IRAK4 degrader KT-474.
  • Kymera is collaborating with Sanofi on the development of degrader candidates targeting IRAK4, including KT-474 (SAR444656), outside of the oncology and immune-oncology fields.
  • KT-333 is a potent and selective heterobifunctional small molecule protein degrader of the STAT3 protein in development for oncology indications.
  • Kymera will hold a webcast for investors on December 14 from 8:00 a.m. to 9:30 a.m. to share clinical data from the KT-474 Phase I patient cohort and oncology pipeline.

Nurix Therapeutics Presents New Preclinical Data Supporting NX-2127 and DeTIL-0255 Clinical Programs at the American Association for Cancer Research Annual Meeting

Retrieved on: 
Friday, April 8, 2022
Clinical Ovarian Cancer & Other Gynecologic Malignancies, Private Securities Litigation Reform Act, Therapy, Cell cycle, DNA, Investor, Forward-looking statement, B-cell lymphoma, Clinical trial, Survival, AACR, SEC, American Association, Neoplasm, Cancer, Chronic lymphocytic leukemia, DNA repair, Lymphoid leukemia, Immunotherapy, Association, American Association for Cancer Research, TILS, Intention, Immunomodulatory imide drug, TIL, Goal, Nasdaq, COVID-19, DNA replication, GLOBE, BTK, Gene, Enzyme, Annual report, Mouse, Protein, Patient, Medical imaging, Pharmaceutical industry, Vaccine, Aeolus

SAN FRANCISCO, April 08, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs, today announced the presentation of preclinical data that support the clinical development of investigative therapies NX-2127 and DeTIL-0255, for the treatment of B-cell malignancies and solid tumors, respectively, at the American Association for Cancer Research (AACR) Annual Meeting. The meeting is being held from April 8-13, 2022 in New Orleans, LA.

Key Points: 
  • We plan to provide clinical updates from both programs in the second half of 2022.
  • In a model of diffuse large B-cell lymphoma, data demonstrate that once-daily oral dose of NX-2127 promoted BTK and Aiolos degradation leading to complete tumor regression.
  • The potent degradation of Ikaros by NX-2127 in mantle cell lymphoma cells lines directly correlates to its superior anti-tumor activity.
  • Nurix has an open Phase 1 clinical trial to evaluate NX-0255-treated TILs (DeTIL-0255) in adults with gynecological malignancies.

Nurix Therapeutics Reports Fiscal First Quarter 2022 Financial Results and Provides a Corporate Update

Retrieved on: 
Thursday, April 7, 2022
Clinical Ovarian Cancer & Other Gynecologic Malignancies, Private Securities Litigation Reform Act, Therapy, Degenerative disease, Intention, Innovation, Investment, Forward-looking statement, United Kingdom, Clinical trial, Collaboration, Health care, AACR, SEC, Research, PD, Neoplasm, American Association, Cancer, Â, Ovarian cancer, Lymphoid leukemia, Endometrial cancer, Association, MHRA, Immunomodulatory imide drug, American Association for Cancer Research, Annual general meeting, Safety, Calendar, Goal, Cervical cancer, TIL, Nasdaq, COVID-19, GLOBE, BTK, Enzyme, Annual report, SAN, Protein, Patient, Pharmaceutical industry, Fine chemical, Sanofi

SAN FRANCISCO, April 07, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs, today reported financial results for the first quarter ended February 28, 2022 and provided a corporate update.

Key Points: 
  • Nurix is conducting its Phase 1 clinical trial of NX-2127 at multiple clinical sites in the United States.
  • Detailed clinical results from the Phase 1a portion of the trial will be presented in the second half of 2022.
  • Nurix anticipates providing a clinical update from the run-in portion of the DeTIL-0255 Phase 1 study in the second half of 2022.
  • Additional information will also be set forth in Nurixs Quarterly Report on Form 10-Q for the fiscal quarter ended February 28, 2022.

Nurix Therapeutics to Present Preclinical Data from Its Novel BTK Degrader (NX-2127) and CBL-B Inhibitor (NX-0255) Programs at the American Association for Cancer Research Annual Meeting

Retrieved on: 
Tuesday, March 8, 2022
Nasdaq, AACR, Clinical trial, SAN, Private Securities Litigation Reform Act, Enzyme, Melanoma, Annual general meeting, Annual report, Cancer, Protein, Date, Lymphoma, BTK, PM, TILS, Chronic lymphocytic leukemia, Intention, GLOBE, Immunotherapy, Patient, American Association, Immunomodulatory imide drug, 2021 Essex County Council election, COVID-19, Therapy, Time, Neoplasm, SEC, Association, Clinical Ovarian Cancer & Other Gynecologic Malignancies, Goal, Forward-looking statement, American Association for Cancer Research, Pharmaceutical industry

Nurix has an open Phase 1 clinical trial to evaluate NX-0255-treated TILs (DeTIL-0255) in adults with gynecological malignancies.

Key Points: 
  • Nurix has an open Phase 1 clinical trial to evaluate NX-0255-treated TILs (DeTIL-0255) in adults with gynecological malignancies.
  • NX-2127 is a novel bifunctional molecule that degrades Brutons tyrosine kinase (BTK) and IMiD neosubstrates.
  • NX-2127 is currently being evaluated in a Phase 1a/1b clinical trial in patients with relapsed or refractory B cell malignancies.
  • Nurix expects to present additional data from this study in the second half of 2022.

Kymera Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Provides a Business Update

Retrieved on: 
Thursday, February 24, 2022
Risk, HS, NYU, SAD, Security (finance), COVID-19, Hidradenitis suppurativa, Therapy, Sanofi, Company, AD, Private Securities Litigation Reform Act, Research, Lymphoma, Development, Apoptosis, Degenerative disease, MDM2, Growth, Investment, Atopic dermatitis, Lymphatic system, Safety, Disease, U.S. Securities and Exchange Commission, Skin, Drug discovery, Goal, CEO, Autoimmunity, Program, Cash, Doctor of Philosophy, Entrepreneurship, Completeness, NASDAQ, Administration, PBMC, Controlled Impact Demonstration, Cancer, Rheumatoid arthritis, Patient, Immunomodulatory imide drug, GLOBE, IFN, University, Annual report, STAT3, Biology, RA, FDA, MAD, University of Washington Department of Global Health, Vaccine, Pharmaceutical industry, Fine chemical, Animal, Video game, Black Majesty, IND, Vertex, IRAK4

Kymera is collaborating with Sanofi on the development of degrader candidates targeting IRAK4, including KT-474 (SAR444656), outside of the oncology and immune-oncology fields.

Key Points: 
  • Kymera is collaborating with Sanofi on the development of degrader candidates targeting IRAK4, including KT-474 (SAR444656), outside of the oncology and immune-oncology fields.
  • In 4Q of 2021, Kymera nominated KT-253, its first-in-class MDM2 degrader as development candidate, which is now in IND enabling activities.
  • Cash and Cash Equivalents: As of December 31, 2021, Kymera had approximately $567.6 million in cash, cash equivalents, and investments.
  • Kymera Therapeutics explicitly disclaims any obligation to update any forward-looking statements.

HaemaLogiX and Lonza Collaborate to Manufacture KappaMab, a Multiple Myeloma Drug Candidate

Retrieved on: 
Thursday, January 27, 2022
KMA, Immunomodulatory imide drug, CN, AL amyloidosis, B cell, Death, Research, Clinical trial, Multiple myeloma, Dexamethasone, CHF, CORE, Coronavirus Scientific Advisory Board (Turkey), Carmine, Bone marrow, Lenalidomide, SAB, Patient, Immune system, CGMP, CEO, Fine chemical, Vaccine, Pharmaceutical industry

Lonza to manufacture drug substance for clinical supply of HaemaLogiX's lead multiple myeloma drug candidate, KappaMab, at its new state-of-the-art facility in Guangzhou (CN)

Key Points: 
  • Lonza to manufacture drug substance for clinical supply of HaemaLogiX's lead multiple myeloma drug candidate, KappaMab, at its new state-of-the-art facility in Guangzhou (CN)
    HaemaLogiX will leverage Lonza's regulatory expertise, global manufacturing footprint, and extensive experience in manufacturing monoclonal antibodies
    BASEL, Switzerland and SYDNEY, Jan. 27, 2022 /PRNewswire/ -- HaemaLogiX Ltd (HaemaLogiX), the clinical-stage biotechnology company developing novel monoclonal antibody therapies for multiple myeloma, and Lonza, a global development and manufacturing partner to the pharma, biotech and nutrition industries, have entered into an agreement to manufacture the next clinical batch (cGMP) of HaemaLogiX's lead multiple myeloma drug candidate, KappaMab.
  • Jeetendra Vaghjiani, Executive Director, Clinical Development & Strategic Marketing, Lonza, commented: "We are looking forward to building a collaboration with HaemaLogiX to help advance their multiple myeloma candidate towards commercial launch.
  • Formed in 2014, HaemaLogiX is a public unlisted biotech company researching antibody therapies for multiple myeloma.
  • Our current research and clinical trial partners are global leaders in Multiple Myeloma and AL Amyloidosis therapy.

Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides a Corporate Update

Retrieved on: 
Thursday, January 27, 2022
Immunomodulatory imide drug, Endometrial cancer, Research, Nasdaq, Forward-looking statement, COVID-19, Investment, SEC, Chronic lymphocytic leukemia, Clinical trial, Ovarian cancer, Private Securities Litigation Reform Act, Lymphoid leukemia, Degenerative disease, TIL, Therapy, BTK, SAN, Enzyme, Exercise, Achievement, Lymphatic system, Annual report, Goal, Cancer, Protein, Patient, Lymphocytosis, Cervical cancer, Drug discovery, Intention, United Kingdom, PD, Clinical Ovarian Cancer & Other Gynecologic Malignancies, CLL, GLOBE, Safety, Information technology, Fine chemical, Pharmaceutical industry, Vaccine, Sanofi

SAN FRANCISCO, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs, today reported financial results for the fourth quarter and fiscal year ended November 30, 2021 and provided a corporate update.

Key Points: 
  • SAN FRANCISCO, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs, today reported financial results for the fourth quarter and fiscal year ended November 30, 2021 and provided a corporate update.
  • 2021 was a remarkable year for Nurix with the advancement of four wholly owned drug candidates into clinical development.
  • The net proceeds to Nurix from the offering were approximately $150.2 million, after deducting underwriting discounts, commissions and offering expenses.
  • Combined with additional capital from partners in 2021, Nurix ended fiscal year 2021 with $432.9 million in cash and equivalents compared to $372.0 million as of November 30, 2020.

iTeos Provides Clinical Development Plans and Promotes Yvonne McGrath, Ph.D. to Chief Scientific Officer

Retrieved on: 
Monday, January 10, 2022
Clinical trial, PD-1, SEC, Safety, Dexamethasone, MediGene, Immunomodulatory imide drug, Standard of care, Drug discovery, Fred Hutchinson Cancer Research Center, United States Patent and Trademark Office, Melanoma, Security (finance), Head, College of Medicine, Leadership, Patient, Cancer, Immunosuppression, Birth certificate, Immunocore, U.S. Securities and Exchange Commission, Forward-looking statement, Neoplasm, FC, Partnership, Doctor of Philosophy, Review, Research, Therapy, Private Securities Litigation Reform Act, Immunotherapy, Biomarker, Company, Risk, Nasdaq, University, University of Wales, Newport, COVID-19, GLOBE, R&D, Patent, GSK, Pharmaceutical industry, Vaccine, A2A, Talimogene laherparepvec

iTeos also announced the promotion of Yvonne McGrath, Ph.D., to chief scientific officer.

Key Points: 
  • iTeos also announced the promotion of Yvonne McGrath, Ph.D., to chief scientific officer.
  • I am also thrilled to announce Dr. McGraths promotion to chief scientific officer.
  • Prior to iTeos, Dr. McGrath served as the chief scientific officer at Complix N.V. and as Head of Development at Immunocore.
  • Any of the foregoing risks could materially and adversely affect iTeos business, results of operations and the trading price of iTeos common stock.

Kymera Therapeutics Announces Key 2022 Goals and Milestones to Support Its Evolution into a Fully Integrated Degrader Medicines Company

Retrieved on: 
Monday, January 10, 2022
LinkedIn, PTCL, U.S. Securities and Exchange Commission, Controlled Impact Demonstration, Program, SAD, Apoptosis, Communication, Lymphoma, G&A, Problem solving, Compte rendu, Immunomodulatory imide drug, Biology, Security (finance), Goal, Lymphatic system, CTCL, HS, Boston, PBMC, Science, CEO, Leukemia, Cytokine, Private Securities Litigation Reform Act, Doctor of Philosophy, Boston Business Journal, Neoplasm, Therapy, Biotechnology, PK, Safety, Drug discovery, Investor, Patient, Entrepreneurship, Uveal melanoma, Large granular lymphocytic leukemia, AD, MAD, AML, Research, Nasdaq, COVID-19, Twitter, GLOBE, Risk, Vertex Pharmaceuticals, Skin, Disease, Growth, Conference, NASDAQ, IND, MDM2, DLBCL, STAT3, Medicine, Pharmaceutical industry, Fine chemical, MYD88, IRAK4, Company, Sanofi, Black Majesty

Kymera is collaborating with Sanofi on the development of degrader candidates targeting IRAK4, including KT-474 (SAR444656), outside of the oncology and immune-oncology fields.

Key Points: 
  • Kymera is collaborating with Sanofi on the development of degrader candidates targeting IRAK4, including KT-474 (SAR444656), outside of the oncology and immune-oncology fields.
  • In 4Q21, Kymera announced IND clearance of KT-413, the companys potent degrader of IRAK4 and IMiD substrates.
  • The Companys goal is to become a fully integrated biopharmaceutical company with a pipeline of novel medicines targeting disease-causing proteins that were previously intractable.
  • Nello Mainolfi, PhD, Co-Founder, President and CEO of Kymera, will provide an overview of the Companys progress and anticipated milestones for 2022.